Veracyte Appoints Dr. Kevin Haas as Chief Development and Technology Officer
VCYT sits 46% above its 52-week low of $22.61.
Summary
Veracyte announced the appointment of Dr. Kevin Haas, formerly of Myriad Genetics, as its new Chief Development and Technology Officer, effective March 24, 2026, a strategic move to enhance its technology and development capabilities.
Key Events · Executive and Board Changes · VCYT
-
New Chief Development and Technology Officer Appointed
Dr. Kevin Haas has been appointed as Veracyte's Chief Development and Technology Officer, effective March 24, 2026.
-
Strategic Executive Hire from Competitor
Dr. Haas previously served as Chief Technology Officer at Myriad Genetics, Inc., bringing valuable experience in genetic testing and precision medicine to Veracyte.
-
Compensation Package Detailed
His compensation includes an annual base salary of $500,000, eligibility for a 55% target annual bonus, and equity awards with a target value of $3,000,000.
Analysis · VCYT · Industrial Applications And Services
Veracyte has appointed Dr. Kevin Haas, previously the Chief Technology Officer at Myriad Genetics, as its new Chief Development and Technology Officer. This is a significant strategic hire, bringing in an executive with a strong background in genetic testing and precision medicine from a competitor. His expertise is expected to bolster Veracyte's technology and development initiatives. The compensation package, including a $500,000 base salary and $3,000,000 in target equity awards, reflects the importance of this role and the company's investment in its leadership team.
At the time of this filing, VCYT was trading at $32.92 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $22.61 to $50.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.